Mast Cell Activation Syndrome: Symptoms, Diagnosis, Triggers and Treatment Explained
Mast Cell Activation Syndrome, usually shortened to MCAS, is a condition in which mast cells release unusually large amounts of inflammatory chemicals during repeated episodes.
These chemicals include histamine, tryptase, prostaglandins and leukotrienes. When released in the right amount, they help protect the body. When too many are released at once, however, they can cause symptoms resembling a severe allergic reaction.
MCAS has received growing attention online, but it is also frequently misunderstood. Flushing, digestive problems, headaches and fatigue can occur in many different conditions. Having these symptoms alone does not necessarily mean that someone has MCAS.
A proper diagnosis requires a combination of characteristic attacks, laboratory evidence of mast-cell activation and a meaningful response to treatment.
What are mast cells?
Mast cells are immune cells found throughout the body. They are especially common in tissues that come into contact with the outside world, including:
The skin
The lungs and airways
The digestive system
The lining of blood vessels
The mouth and nose
Mast cells contain small storage compartments called granules. Inside these granules are powerful chemical messengers.
Simple diagram: how a mast cell reacts
Possible trigger
Food, medicine, insect sting, heat, infection or another stimulus
│
▼
┌─────────────┐
│ Mast cell │
│ ● ● ● ● ● │
└─────────────┘
│
Cell is activated
│
▼
Histamine • Tryptase • Leukotrienes
Prostaglandins • Cytokines
│
▼
Flushing • Itching • Swelling • Wheezing • Diarrhoea
Low blood pressure • Rapid heartbeat
This release of chemicals is called mast-cell degranulation or mast-cell mediator release.
In ordinary allergies, mast cells may respond to a particular allergen, such as peanuts or insect venom. In MCAS, episodes of systemic mast-cell activation occur repeatedly and may not always have an obvious trigger.
What is Mast Cell Activation Syndrome?
MCAS is not simply “high histamine” or general food intolerance.
Under widely used consensus criteria, MCAS describes recurrent attacks involving symptoms typical of systemic mast-cell activation. The episodes generally affect at least two organ systems at the same time.
For example, a person might experience:
Flushing and hives
Abdominal cramping and diarrhoea
Wheezing or throat swelling
A rapid pulse and a fall in blood pressure
The symptoms may range from uncomfortable to life-threatening.
Importantly, MCAS is a syndrome rather than one single disease. Doctors may classify it according to its underlying cause.
Main forms of MCAS
Primary or clonal MCAS
The mast cells themselves are abnormal. Some patients have an underlying clonal mast-cell disorder, such as systemic mastocytosis or monoclonal mast-cell activation syndrome.
Secondary MCAS
The mast cells are reacting to another identifiable problem. Examples can include IgE-mediated allergy, certain drug reactions or other immune processes.
Idiopathic MCAS
The person meets the diagnostic criteria for MCAS, but investigations do not identify a clonal mast-cell disorder or a clear secondary cause.
What symptoms can MCAS cause?
Symptoms differ significantly between individuals. More importantly, the recognised MCAS pattern is usually episodic and systemic rather than a single mild symptom that remains unchanged every day.
Skin
Mast-cell mediators can affect the skin and small blood vessels, causing:
Flushing
Hives
Itching
Redness
Swelling beneath the skin
A feeling of warmth
Digestive system
Possible gastrointestinal symptoms include:
Cramping abdominal pain
Nausea
Vomiting
Diarrhoea
These symptoms are common in many digestive conditions, so they are not specific to MCAS.
Heart and circulation
Histamine and other mediators can widen blood vessels and alter circulation. Symptoms may include:
Light-headedness
A rapid heartbeat
Fainting
Low blood pressure
Collapse during severe attacks
Lungs and airways
Respiratory symptoms can include:
Wheezing
Shortness of breath
Nasal congestion
Throat tightness
Breathing difficulty or throat swelling can indicate anaphylaxis and requires urgent medical attention.
Nervous system and general symptoms
Some patients also report:
Headaches
Difficulty concentrating
Weakness
Marked tiredness
However, symptoms such as fatigue, dizziness and poor concentration are non-specific. They can be caused by anaemia, thyroid disease, sleep disorders, infection, medication side effects and numerous other conditions.
They should not be used by themselves to diagnose MCAS.
Body-system diagram
MAST-CELL MEDIATORS
│
┌─────────────┬───────┼────────┬──────────────┐
▼ ▼ ▼ ▼ ▼
Skin Gut Airways Circulation Other effects
│ │ │ │ │
Flushing Cramps Wheeze Fast pulse Headache
Hives Vomiting Breathless Low BP Weakness
Itching Diarrhoea Fainting Fatigue
Swelling
What can trigger an MCAS episode?
Triggers are highly individual. A suspected trigger should not automatically be removed from someone’s diet or lifestyle without considering other explanations.
Reported triggers may include:
Heat or sudden temperature changes
Alcohol
Insect stings
Certain medicines
Physical exertion
Emotional stress
Infections
Particular foods
Strong smells
Friction or pressure on the skin
In some people, episodes appear without an identifiable trigger.
Keeping a record of the timing, circumstances and symptoms of attacks may help clinicians identify patterns. It is usually more useful than following a long, restrictive avoidance list taken from social media.
How is MCAS diagnosed?
There is no single routine test that confirms every case of MCAS. Diagnosis normally requires all three parts of the recognised clinical framework.
The three-part diagnostic approach
1. Typical repeated systemic episodes
+
2. Objective rise in a mast-cell mediator
+
3. Improvement with mast-cell-directed treatment
=
MCAS may be diagnosed
1. Characteristic systemic episodes
The patient should experience recurrent, significant symptoms consistent with mast-cell mediator release.
Symptoms generally involve at least two organ systems at the same time, such as:
Skin plus digestive symptoms
Skin plus breathing symptoms
Digestive symptoms plus low blood pressure
Flushing plus wheezing and faintness
A collection of persistent, non-specific symptoms without clear episodes is less supportive of MCAS.
2. Laboratory evidence of mast-cell activation
The preferred biochemical marker is often serum tryptase.
Tryptase should ideally be measured during an attack, usually as soon as practical and within approximately four hours of symptom onset. A separate baseline sample is taken when the person is well, commonly at least 24 hours after symptoms have resolved.
A significant rise is commonly calculated using the following formula:
Significant acute tryptase level =
Baseline tryptase × 1.2 + 2 ng/mL
For example:
Baseline tryptase: 5 ng/mL
5 × 1.2 + 2 = 8 ng/mL
An acute result of 8 ng/mL or more would meet the
laboratory rise defined by this formula.
A result does not have to exceed the laboratory’s usual “normal range” to represent a significant rise from that individual’s baseline.
Other possible tests include urinary mast-cell mediator measurements, such as:
N-methylhistamine
Leukotriene E4
Prostaglandin-related metabolites
The usefulness and availability of these tests vary. Collection timing, storage and handling can also influence results.
3. Response to mast-cell-directed treatment
The third criterion is a clear reduction in attacks or symptoms after treatment that blocks mast-cell mediators or limits their release.
A treatment response can support the diagnosis, but it is not enough on its own. Antihistamines can improve ordinary allergies, urticaria and several other conditions.
What other conditions can resemble MCAS?
Because MCAS symptoms can affect several organs, clinicians must consider alternative diagnoses.
These may include:
IgE-mediated food or drug allergy
Chronic spontaneous urticaria
Asthma
Hereditary or acquired angioedema
Vasovagal fainting
Postural tachycardia syndromes
Carcinoid syndrome
Phaeochromocytoma
Thyroid disease
Inflammatory bowel disease
Irritable bowel syndrome
Medication side effects
Panic attacks
Menopausal flushing
Systemic mastocytosis
Hereditary alpha-tryptasaemia
A person may also have more than one condition at the same time.
The purpose of considering these alternatives is not to dismiss symptoms. It is to avoid missing another illness that requires a different treatment.
MCAS, mastocytosis and ordinary allergies
These terms are sometimes used as though they mean the same thing, but they describe different problems.
| Condition | What happens? |
|---|---|
| Ordinary allergy | The immune system reacts to a specific allergen, often through IgE antibodies. |
| MCAS | Recurrent systemic episodes occur because excessive mast-cell mediators are released. |
| Mastocytosis | Abnormal mast cells accumulate in the skin, bone marrow or other organs. |
| Hereditary alpha-tryptasaemia | An inherited genetic trait can lead to increased baseline tryptase and variable symptoms. |
Someone with mastocytosis may experience mast-cell activation, but MCAS does not automatically mean that the person has mastocytosis.
How is MCAS treated?
Treatment is individualised and should be supervised by a clinician familiar with allergy or mast-cell disorders.
The main objectives are to:
Treat severe reactions promptly.
Block the effects of released mediators.
Reduce mast-cell activation.
Identify and manage underlying causes.
Avoid confirmed triggers without creating unnecessary restrictions.
H1 antihistamines
H1 antihistamines are often used for symptoms such as:
Hives
Itching
Flushing
Swelling
Modern non-sedating antihistamines may be preferred for regular use, although the choice and dose should be discussed with a clinician.
H2 antihistamines
H2 receptor blockers act on a different type of histamine receptor. They may help some gastrointestinal symptoms and are sometimes combined with an H1 antihistamine.
Leukotriene-modifying medicines
Medicines that block leukotriene pathways may be considered when leukotrienes appear to contribute to respiratory or other symptoms.
Mast-cell stabilisers
Sodium cromoglicate, also called cromolyn in some countries, may help selected patients, particularly those with gastrointestinal symptoms.
Omalizumab
Omalizumab is an injectable medicine that targets free IgE. Specialists may consider it for selected patients with recurrent severe reactions, particularly when other treatments have not provided adequate control.
Adrenaline for anaphylaxis
People considered at risk of anaphylaxis may be prescribed adrenaline auto-injectors.
Symptoms that may indicate anaphylaxis include:
Difficulty breathing
Throat or tongue swelling
Collapse or severe faintness
Sudden low blood pressure
Rapidly progressing symptoms affecting several body systems
Anaphylaxis is a medical emergency. Adrenaline should be used according to the person’s emergency plan, followed by an immediate call to emergency services.
Other treatment considerations
Additional medicines may sometimes be used by specialists according to the individual’s symptoms and underlying diagnosis.
Treatment should be introduced systematically where possible. Starting several medicines, supplements and restrictive diets at the same time makes it difficult to determine what is helping or causing side effects.
Does a low-histamine diet treat MCAS?
Some people report that particular foods worsen their symptoms, but there is no single universally effective “MCAS diet”.
The histamine content of food can vary according to:
Freshness
Storage
Processing
Fermentation
Preparation method
Online food lists also frequently contradict one another.
A short, structured dietary trial may occasionally be useful under professional guidance. Long-term broad food restriction can create nutritional deficiencies, anxiety around food and unintended weight loss.
Where food reactions are suspected, assessment by an allergy specialist and a registered dietitian is preferable to removing numerous food groups without a plan.
Living with suspected or diagnosed MCAS
A practical symptom diary can include:
Date and time of the episode
Symptoms and body systems involved
Food and medicines taken beforehand
Exercise, infection, heat or insect exposure
Menstrual-cycle timing where relevant
Treatment taken
Response to treatment
Photographs of visible swelling or hives
Blood pressure or pulse readings when safely available
The aim is to identify repeatable patterns—not to record every minor sensation throughout the day.
Patients at risk of severe reactions should also have a written emergency plan and ensure that they understand how and when to use prescribed adrenaline.
Why is MCAS controversial?
MCAS is a recognised clinical syndrome, but uncertainty remains around its boundaries, frequency and relationship with broader groups of chronic symptoms.
One reason for disagreement is that the term is sometimes applied to people who do not meet established criteria. Symptoms including fatigue, food sensitivity, headache and digestive discomfort are real, but they are not specific to mast-cell activation.
Overdiagnosis may lead to:
Missing the actual cause of symptoms
Unnecessary medication
Highly restrictive diets
Expensive unvalidated testing
Anxiety about ordinary foods and environments
Underdiagnosis is also possible, particularly when severe episodes are not investigated at the right time.
The balanced approach is to take symptoms seriously while requiring objective evidence before labelling them as MCAS.
Key points to remember
MCAS involves recurrent systemic episodes of mast-cell mediator release.
Typical attacks may cause flushing, hives, swelling, diarrhoea, wheezing, a rapid heartbeat or low blood pressure.
Diagnosis generally requires:
Typical symptoms affecting at least two organ systems.
Objective evidence of mast-cell activation.
Improvement with mast-cell-targeted treatment.
Serum tryptase is most informative when an acute sample is compared with the person’s baseline level.
MCAS is not the same as ordinary allergy or mastocytosis.
Treatment may include antihistamines, leukotriene-modifying medicines, mast-cell stabilisers and, in selected cases, specialist therapies.
Severe breathing difficulty, throat swelling or collapse should be treated as a medical emergency.
Medical disclaimer
This article is for general educational purposes only. It is not a diagnosis or a substitute for personalised medical advice.
Anyone experiencing severe breathing difficulty, throat or tongue swelling, collapse or rapidly worsening allergic symptoms should seek emergency medical assistance immediately.
People who suspect MCAS should discuss their symptoms with a qualified healthcare professional, ideally one experienced in allergy, immunology or mast-cell disorders.
References
Gülen T. Using the right criteria for MCAS. Current Allergy and Asthma Reports. 2024.
Castells M, Butterfield J. Mast cell activation syndrome: current understanding and research needs. Journal of Allergy and Clinical Immunology. 2024.
Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(4):1125–1133.
Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646.
Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. Journal of Allergy and Clinical Immunology. 2010;126(6):1099–1104.e4.
American Academy of Allergy, Asthma & Immunology. Mast Cell Activation Syndrome. AAAAI patient information.
Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group report: mast cell activation syndrome. Journal of Allergy and Clinical Immunology. 2019;144(4):883–896.
Lee E, et al. Diagnosis and management of mast cell activation syndrome. Allergy, Asthma & Clinical Immunology. 2025.
Australasian Society of Clinical Immunology and Allergy. Diagnosis and investigation of mast cell activation disorders and syndrome. ASCIA position paper. 2025.
Akin C, et al. Diagnosis and management of patients with mast cell activation syndromes: current diagnostic standards, differential diagnoses and treatment options. Journal of Allergy and Clinical Immunology: In Practice. 2025–2026.
MCAS Awareness Mug
Histamine Happens
A colourful and uplifting mug for people living with Mast Cell Activation Syndrome, histamine intolerance, mastocytosis and other invisible health conditions.
“I adapt. I manage. I keep going.”
Mast cells release chemicals such as histamine as part of the immune response. For people managing MCAS and related conditions, symptoms can be unpredictable. This mug offers a simple reminder of resilience, strength and the ability to keep moving forward.
- Thoughtful MCAS awareness gift
- Ideal for chronic illness and invisible illness support
- Modern molecule-inspired design
- Perfect for tea, coffee or a favourite warm drink
Awareness product only. This mug is not a medical device and does not diagnose, treat or prevent any medical condition.